Monthly sales of OTC Allegra rise 30% on average
By Jung, Sae-Im | translator Kim, Jung-Ju
23.02.27 16:15:27
가나다라
0
The only 3rd generation antihistamine drug approved as OTC...settles in the market in the first year of its release
Preannounces plans to conduct aggressive marketing activities...to highlight it as an “Allergy drug with a quick effect that brings no concern over drowsiness”
According to the market research institution IQUVA, sales of the OTC Allegra have risen 29% on average per month, ever since its release in March to the allergy season in October of the same year. Since its launch, 44% of pharmacies nationwide have been supplying Allegra.
Allegra’s sales had risen significantly during the spring and fall season when allergic rhinitis worsens. Its sales, which had been in the KRW 20 million range in the first month of March of last year, had risen over fivefold to KRW 120 million in April. Ev
Jung, Sae-Im(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)